Drawing for EVOLVERAI

USPTO serial 98614898

EVOLVERAI

Reviewed by CopyMark Law Group

Status 731Notice of Allowance
Filing date
Status date
Registration date
—
Examiner
GARCIA, CLAUDIA
Law office
INTENT TO USE SECTION

What this means

The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.

Status 731: Status 731 means the second six-month extension to file a Statement of Use was granted. File a Statement of Use or the next extension before the deadline expires.

Need help with EVOLVERAI?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $648*

Plus Government fees of $300

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Brendan J. Hughes

Brendan J. Hughes Cooley LLP1299 Pennsylvania Avenue, NW, Suite 700Washington, DC 20004United States

Goods and services

ClassDescriptionStatusFirst use
009Downloadable computer software using artificial intelligence for automated machine learning in the field of drug design and development; Downloadable computer software using artificial intelligence for collecting, analyzing, interpreting, and reporting data and information for drug design and development; Downloadable computer software using artificial intelligence for automated machine learning for drug design and development in the fields of neuroscience and immuno-oncology; Downloadable computer software using artificial intelligence for the discovery and development of therapeutic agents and indices in the fields of pharmaceuticals, biopharmaceuticals, and healthcare; Downloadable computer software using artificial intelligence for the discovery and development of therapeutic agents and indices in the fields of neuroscience and immune-oncology; Downloadable computer software for molecular research, research and develop and development of pharmaceutical products and chemical compounds, and analysis of biological or chemical activity in the fields of pharmaceuticals, biopharmaceuticals, and healthcare; Downloadable artificial intelligence software for diagnostic and therapeutic use, and for data mining in connection with pharmaceutical drug discovery, development, and response prediction in the fields of neuroscience and immune-oncology; Downloadable software using artificial intelligence and incorporating computational methods and machine learning models for the design and characterization of biologic therapeutic products and drug analysis in drug discovery and development.ACTIVE—
042Providing online nondownloadable computer software using artificial intelligence for automated machine learning in the field of drug design and development; Providing online nondownloadable computer software using artificial intelligence for collecting, analyzing, interpreting, and reporting data and information for drug design and development; Providing online nondownloadable computer software using artificial intelligence for automated machine learning for drug design and development in the fields of neuroscience and immune-oncology; Providing online nondownloadable computer software using artificial intelligence for the discovery and development of therapeutic agents and indices in the fields of pharmaceuticals, biopharmaceuticals, and healthcare; Providing online nondownloadable computer software using artificial intelligence for the discovery and development of therapeutic agents and indices in the fields of neuroscience and immune-oncology; Providing online nondownloadable software for molecular research, research and development of pharmaceutical products and chemical compounds, and analysis of biological or chemical activity in the fields of pharmaceuticals, biopharmaceuticals, and healthcare; Providing online nondownloadable artificial intelligence software for diagnostic and therapeutic use, and for data mining in connection with pharmaceutical drug discovery, development, and response prediction in the fields of neuroscience and immuno-oncology; Providing online nondownloadable software using artificial intelligence and incorporating computational methods and machine learning models for the design and characterization of biologic therapeutic products and drug analysis in drug discovery and development; Platform as a service (PaaS) featuring computer software platforms using artificial intelligence for automated machine learning in the field of drug design and development; Platform as a service (PaaS) featuring computer software platforms using artificial intelligence for collecting, analyzing, interpreting, and reporting data and information for drug design and development; Platform as a service (PaaS) featuring computer software platforms using artificial intelligence for automated machine learning for drug design and development in the fields of neuroscience and immune-oncology; Platform as a service (PaaS) featuring computer software platforms using artificial intelligence for the discovery and development of therapeutic agents and indices in the fields of pharmaceuticals, biopharmaceuticals, and healthcare; Platform as a service (PaaS) featuring computer software platforms using artificial intelligence for the discovery and development of therapeutic agents and indices in the fields of neuroscience and immune-oncology; Platform as a service (PaaS) featuring computer software platforms for molecular research, research and development of pharmaceutical products and chemical compounds, and analysis of biological or chemical activity in the fields of pharmaceuticals, biopharmaceuticals, and healthcare; Platform as a service (PaaS) featuring computer software platforms using artificial intelligence for diagnostic and therapeutic use, and for data mining in connection with pharmaceutical drug discovery, development, and response prediction in the fields of neuroscience and immuno-oncology; Platform as a service (PaaS) featuring computer software platforms using artificial intelligence and incorporating computational methods and machine learning models for the design and characterization of biologic therapeutic products and drug analysis in drug discovery and development; Pharmaceutical and biopharmaceutical research and development; Pharmaceutical and biopharmaceutical research and development in the fields of neuroscience and immuno-oncology; Scientific and medical research in the fields of pharmaceuticals, biologic testing and interpretation, neuroscience, and immuno-oncology; Research and development of pharmaceuticals, biological preparations, and therapeutic products and medicines.ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 7, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 6, 2026EX2GSOU EXTENSION 2 GRANTED—
Aug 6, 2026EXT2SOU EXTENSION 2 FILED—
Aug 6, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 12, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 11, 2026EX1GSOU EXTENSION 1 GRANTED—
Feb 11, 2026EXT1SOU EXTENSION 1 FILED—
Feb 11, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 12, 2025NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jun 17, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jun 17, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 11, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
May 15, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 18, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 18, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 18, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 18, 2025GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 18, 2025GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 18, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 14, 2025DOCKASSIGNED TO EXAMINER—
Jan 13, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 24, 2024NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance